DJIA 17,888.35 168.43 0.95%
NASDAQ 5,156.31 47.64 0.93%
S&P 500 2,102.63 22.22 1.07%
market minute promo

Celgene (NASDAQ: CELG)

110.56 1.11 (1.01%)

REAL-TIME: Last trade at

Extended Hours: $110.64 $0.07 (0.06%)
Quote as of (NASDAQ)

company name or ticker

Recent Quotes

CELG $110.56 1.01%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $110.27
Previous Close $109.45
Daily Range $109.03 - $111.39
52-Week Range $92.98 - $140.72
Market Cap $86.9B
P/E Ratio 55.00
Dividend (Yield) $0.00 (0.0%)
Volume 4,319,330
Average Daily Volume 4,701,383
Current FY EPS $4.19




Drug Makers

Celgene (CELG) Description

A biopharmaceutical company primarily engaged in the discovery, development and commercialization of innovative therapies designed to treat cancer and immune-inflammatory related diseases. Website:

News & Commentary Rss Feed

The World's Largest Investing Firm Bought These 2 Biotech Stocks: Should You?

BlackRock purchased shares of both Biogen and Celgene last quarter. Is it time for retail investors to do the same?

Stock Market News for December 01, 2015

VUG, MA, CELG, ABBV: Large Inflows Detected at ETF

Can Bristol-Myers Squibb And AbbVie's Empliciti Become a Top Seller?

The FDA's approval of Empliciti could reshape second-line multiple myeloma treatment.

Bristol-Myers Squibb's Opdivo May Change How We Treat Pancreatic Cancer

Combining Opdivo with other medications for pancreatic cancer could offer new hope to patients.

3 Healthcare Stocks With Massive Buyback Programs

These company's are spending billions of dollars repurchasing their shares, and that may not be a bad thing.

1 Healthcare Stock That Has It All

The healthcare sector is packed with high-growth, but risky, investment opportunities. However, this healthcare stock appears to have all your bases covered.

Short Sellers Run for Cover From Major Biotechs

Johnson & Johnson's Latest FDA Approval Could Spell Problems for Amgen

Johnson & Johnson's newly approved multiple myeloma drug, Darzalex, is worth keeping an eye on for a number of reasons.

3 Drugs Stocks Dragging The Industry Down

See More CELG News...

CELG's Top Competitors

CELG $110.56 (1.01%)
Current stock: CELG
AMGN $161.98 (0.55%)
Current stock: AMGN
GILD $105.85 (-0.10%)
Current stock: GILD
$0.00 (0.00%)
Current stock: